Thymectacin

Thymectacin (NB-1011, NB-101, N-5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl(phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer prodrug of brivudine monophosphate. It developed by New Biotics and it has entered in phase I clinical trials for colon cancer.